Nestle set to increase stake in Aimmune Therapeutics to $273mn total

By Sean Galea-Pace
Share
The Swiss-based food manufacturing company, Nestle, is set to significantly raise its stake in drug firm, Aimmune Therapeutics, as it begins to submit a...

The Swiss-based food manufacturing company, Nestle, is set to significantly raise its stake in drug firm, Aimmune Therapeutics, as it begins to submit a marketing application for its peanut allergy drug by the end of 2018, Reuters reports.

In a deal expected to be worth $98mn, the agreement will see Nestle’s stake rise to 19% from 14.5% as of the end of February, with its total investment in the company reaching $273mn.

It has also been announced that the companies have increased their two-year strategic pact to create therapies for food allergies by an additional two years.

See more:

Wedbush Securities analyst, Liana Moussatos, commented: “Some investors were worried that Nestle might sell their original equity investment in Aimmune. However, to us, this suggests Nestle views investment in Aimmune as long-term.”

According to Chief Executive Officer, Jayson Dallas, the launch of Aimmune’s oral drug, AR101, is said to be “well beyond” the expected approval and unveiling of the drug in the US.

It is anticipated the drug will be one of the first to be made available to patients in need for treatment options.

Share

Featured Articles

Manufacturing Unwrapped: Manufacturing Leader Jeff Winter

In addition to being our top magazine influencer back in August, Jeff also did an unmissable interview with Manufacturing Digital on IoT

Manufacturing Unwrapped: Kathleen Mitford of Microsoft

This year we had a truly insightful interview with Kathleen Mitford, CVP of Global Industry at Microsoft on its AI Copilot solutions for manufacturing

Can Carton Waste Revolutionise Sustainable Manufacturing?

A new €3.1m Ittervoort facility processes 20,000 tonnes of polyAl annually, turning carton waste into reusable materials for durable manufacturing products

Stellantis & CATL Boost EV Manufacturing Capacity

Sustainability & ESG

Sir David McMurty: A Visionary Engineer, Inventor and Leader

Production & Operations

IFS: Gaining New Manufacturing Value with Service Centricity

Production & Operations